Innate immunity champions: The diverse functions of macrophages.
Chronic diseases
Inflammation
Macrophages
Metabolism
Therapies
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
23 Sep 2024
23 Sep 2024
Historique:
revised:
03
09
2024
received:
27
06
2024
accepted:
05
09
2024
medline:
23
9
2024
pubmed:
23
9
2024
entrez:
23
9
2024
Statut:
aheadofprint
Résumé
Macrophages are instrumental in maintaining tissue homeostasis, modulating inflammation, and driving regeneration. The advent of omics techniques has led to the identification of numerous tissue-specific macrophage subtypes, thereby introducing the concept of the "macrophage niche". This paradigm underscores the ability of macrophages to adapt their functions based on environmental cues, such as tissue-specific signals. This adaptability is closely linked to their metabolic states, which are crucial for their function and role in health and disease. Macrophage metabolism is central to their ability to switch between proinflammatory and anti-inflammatory states. In this regard, environmental factors, including the extracellular matrix, cellular interactions, and microbial metabolites, profoundly influence macrophage behavior. Moreover, diet and gut microbiota significantly impact macrophage function, with nutrients and microbial metabolites influencing their activity and contributing to conditions like inflammatory bowel disease. Targeting specific macrophage functions and their metabolic processes is leading to the development of novel treatments for a range of chronic inflammatory conditions. The exploration of macrophage biology enriches our understanding of immune regulation and holds the promise of innovative approaches to managing diseases marked by inflammation and immune dysfunction, offering a frontier for scientific and clinical advancement.
Identifiants
pubmed: 39308210
doi: 10.1002/eji.202451139
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2451139Subventions
Organisme : KU LEUVEN INTERNAL FUNDS KU Leuven Global PhD Partnerships with the University of Edinburgh
ID : GPUE/20/003
Organisme : Fonds voor Wetenschappelijk Onderzoek Vlaanderen
ID : FWO 1SF4722N
Organisme : FWO
ID : G0D8317N
Organisme : FWO
ID : G0A7919N
Organisme : FWO
ID : G086721N
Organisme : FWO
ID : G088816N
Organisme : FWO
ID : S008419N
Organisme : KU Leuven Internal Funds
ID : C12/15/016C14/17/097
Informations de copyright
© 2024 Wiley‐VCH GmbH.
Références
Hamidzadeh, K., Christensen, S. M., Dalby, E., Chandrasekaran, P. and Mosser, D. M., Macrophages and the recovery from acute and chronic inflammation. Annu. Rev. Physiol. 2017. 79: 567–592.
Lazarov, T., Juarez‐Carreño, S., Cox, N. and Geissmann, F., Physiology and diseases of tissue‐resident macrophages. Nature. 2023. 618: 698–707.
Viola, M. F. and Boeckxstaens, G., Niche‐specific functional heterogeneity of intestinal resident macrophages. Gut. 2021. 70: 1383–1395.
Chakarov, S., Lim, H. Y., Tan, L., Lim, S. Y., See, P., Lum, J., Zhang, X. M., et al., Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches. Science. 2019. 363.
Ke, B. J., Abdurahiman, S., Biscu, F., Zanella, G., Dragoni, G., Santhosh, S., De Simone, V., et al., Intercellular interaction between FAP+ fibroblasts and CD150+ inflammatory monocytes mediates fibrostenosis in Crohn's disease. J. Clin. Invest. 2024. 134.
Jaitin, D. A., Adlung, L., Thaiss, C. A., Weiner, A., Li, B., Descamps, H., Lundgren, P., et al., Lipid‐associated macrophages control metabolic homeostasis in a Trem2‐dependent manner. Cell. 2019. 178: 686–698.e14.
Stakenborg, M., Abdurahiman, S., De Simone, V., Goverse, G., Stakenborg, N., Van Baarle, L., Wu, Q., et al., Enteric glial cells favor accumulation of anti‐inflammatory macrophages during the resolution of muscularis inflammation. Mucosal Immunol. 2022. 15: 1296–1308.
Hou, P., Fang, J., Liu, Z., Shi, Y., Agostini, M., Bernassola, F., Bove, P., et al., Macrophage polarization and metabolism in atherosclerosis. Cell Death. Dis. 2023. 14: 691.
Delfini, M., Stakenborg, N., Viola, M. F. and Boeckxstaens, G., Macrophages in the gut: masters in multitasking. Immunity. 2022. 55: 1530–1548.
Morhardt, T. L., Hayashi, A., Ochi, T., Quirós, M., Kitamoto, S., Nagao‐Kitamoto, H., Kuffa, P., et al., IL‐10 produced by macrophages regulates epithelial integrity in the small intestine. Sci. Rep. 2019. 9: 1223.
Miyoshi, H., VanDussen, K. L., Malvin, N. P., Ryu, S. H., Wang, Y., Sonnek, N. M., Lai, C. W., et al., Prostaglandin E2 promotes intestinal repair through an adaptive cellular response of the epithelium. EMBO J. 2017. 36: 5–24.
Muller, P. A., Koscsó, B., Rajani, G. M., Stevanovic, K., Berres, M. L., Hashimoto, D., Mortha, A., et al., Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility. Cell. 2014. 158: 300–313.
Saha, S., Aranda, E., Hayakawa, Y., Bhanja, P., Atay, S., Brodin, N. P., Li, J., et al., Macrophage‐derived extracellular vesicle‐packaged WNTs rescue intestinal stem cells and enhance survival after radiation injury. Nat. Commun. 2016. 7: 13096.
Krause, P., Morris, V., Greenbaum, J. A., Park, Y., Bjoerheden, U., Mikulski, Z., Muffley, T., et al., IL‐10‐producing intestinal macrophages prevent excessive antibacterial innate immunity by limiting IL‐23 synthesis. Nat. Commun. 2015. 6: 7055.
Hegarty, L. M., Jones, G. R. and Bain, C. C., Macrophages in intestinal homeostasis and inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 2023. 20: 538–553.
Na, Y. R., Stakenborg, M., Seok, S. H. and Matteoli, G., Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. Nat. Rev. Gastroenterol. Hepatol. 2019. 16: 531–543.
Nahrendorf, M. and Swirski, F. K., Abandoning M1/M2 for a Network Model of Macrophage Function. Circ. Res. 2016. 119: 414–417.
Browaeys, R., Saelens, W. and Saeys, Y., NicheNet: modeling intercellular communication by linking ligands to target genes. Nat. Methods. 2020. 17: 159–162.
Gorin, G., Fang, M., Chari, T. and Pachter, L., RNA velocity unraveled. PLoS Comput. Biol. 2022. 18: e1010492.
Van de Sande, B., Flerin, C., Davie, K., De Waegeneer, M., Hulselmans, G., Aibar, S., Seurinck, R., et al., A scalable SCENIC workflow for single‐cell gene regulatory network analysis. Nat. Protoc. 2020. 15: 2247–2276.
Browaeys, R., Gilis, J., Sang‐Aram, C., De Bleser, P., Hoste, L., Tavernier, S., Lambrechts, D., et al., MultiNicheNet: a flexible framework for differential cell‐cell communication analysis from multi‐sample multi‐condition single‐cell transcriptomics data. Biorxiv. 2023:2023.06.13.544751.
Gao, M., Qiao, C. and Huang, Y., UniTVelo: temporally unified RNA velocity reinforces single‐cell trajectory inference. Nat. Commun. 2022. 13: 6586.
Lobato‐Moreno, S., Yildiz, U., Claringbould, A., Servaas, N. H., Vlachou, E. P., Arnold, C., Gwendolyn Bauersach, H., et al., Scalable ultra‐high‐throughput single‐cell chromatin and RNA sequencing reveals gene regulatory dynamics linking macrophage polarization to autoimmune disease. Biorxiv. 2024: 2023.12.26.573253.
Stansbury, C. M., Dotson, G. A., Pugh, H., Rehemtulla, A., Rajapakse, I. and Muir, L. A., A lipid‐associated macrophage lineage rewires the spatial landscape of adipose tissue in early obesity. JCI Insight. 2023. 8.
Kii, S., Kitamura, H., Hashimoto, S., Ikeo, K., Ichikawa, N., Yoshida, T., Homma, S., et al., STAT1‐mediated induction of Ly6c‐expressing macrophages are involved in the pathogenesis of an acute colitis model. Inflamm. Res. 2022. 71: 1079–1094.
Manoochehrabadi, S., Arsang‐Jang, S., Mazdeh, M., Inoko, H., Sayad, A. and Taheri, M., Analysis of STAT1, STAT2 and STAT3 mRNA expression levels in the blood of patients with multiple sclerosis. Hum. Antibodies. 2019. 27: 91–98.
Stankey, C. T., Bourges, C., Haag, L. M., Turner‐Stokes, T., Piedade, A. P., Palmer‐Jones, C., Papa, I., et al., A disease‐associated gene desert directs macrophage inflammation through ETS2. Nature. 2024. 630: 447–456.
De Lange, K. M., Moutsianas, L., Lee, J. C., Lamb, C. A., Luo, Y., Kennedy, N. A., Jostins, L., et al., Genome‐wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat. Genet. 2017. 49: 256–261.
Li, G., Hao, W. and Hu, W., Transcription factor PU.1 and immune cell differentiation (review). Int. J. Mol. Med. 2020. 46: 1943–1950.
Chen, Y., Ying, Y., Wang, M., Ma, C., Jia, M., Shi, L., Wang, S., et al., A distal super‐enhancer activates oncogenic ETS2 via recruiting MECOM in inflammatory bowel disease and colorectal cancer. Cell Death. Dis. 2023. 14: 8.
Chen, X., Gao, Y., Xie, J., Hua, H., Pan, C., Huang, J., Jing, M., et al., Identification of FCN1 as a novel macrophage infiltration‐associated biomarker for diagnosis of pediatric inflammatory bowel diseases. J. Transl. Med. 2023. 21: 203.
Al‐Tashi, Q., Saad, M. B., Muneer, A., Qureshi, R., Mirjalili, S., Sheshadri, A., Le, X., et al., Machine learning models for the identification of prognostic and predictive cancer biomarkers: a systematic review. Int. J. Mol. Sci. 2023. 24.
Blériot, C., Chakarov, S. and Ginhoux, F., Determinants of resident tissue macrophage identity and function. Immunity. 2020. 52: 957–970.
Kvedaraite, E., Lourda, M., Mouratidou, N., Düking, T., Padhi, A., Moll, K., Czarnewski, P., et al., Intestinal stroma guides monocyte differentiation to macrophages through GM‐CSF. Nat. Commun. 2024. 15: 1752.
Ouyang, J. F., Mishra, K., Xie, Y., Park, H., Huang, K. Y., Petretto, E. and Behmoaras, J., Systems level identification of a matrisome‐associated macrophage polarisation state in multi‐organ fibrosis. eLife. 2023. 12.
Medchemexpress. Pexidartinib [Available from: https://www.medchemexpress.com/Pexidartinib.html
Schneider, K. M., Blank, N., Alvarez, Y., Thum, K., Lundgren, P., Litichevskiy, L., Sleeman, M., et al., The enteric nervous system relays psychological stress to intestinal inflammation. Cell. 2023. 186: 2823–2838.e20.
van Baarle, L., De Simone, V., Schneider, L., Santhosh, S., Abdurahiman, S., Biscu, F., Schneider, R., et al., IL‐1R signaling drives enteric glia‐macrophage interactions in colorectal cancer. Nat. Commun. 2024. 15: 6079.
Meroni, E., Stakenborg, N., Gomez‐Pinilla, P. J., Stakenborg, M., Aguilera‐Lizarraga, J., Florens, M., Delfini, M., et al., Vagus nerve stimulation promotes epithelial proliferation and controls colon monocyte infiltration during DSS‐induced colitis. Front. Med. (Lausanne). 2021. 8: 694268.
Pinho‐Ribeiro, F. A., Deng, L., Neel, D. V., Erdogan, O., Basu, H., Yang, D., Choi, S., et al., Bacteria hijack a meningeal neuroimmune axis to facilitate brain invasion. Nature. 2023. 615: 472–481.
Lavelle, A. and Sokol, H., Gut microbiota‐derived metabolites as key actors in inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 2020. 17: 223–237.
Muller, P. A., Schneeberger, M., Matheis, F., Wang, P., Kerner, Z., Ilanges, A., Pellegrino, K., et al., Microbiota modulate sympathetic neurons via a gut‐brain circuit. Nature. 2020. 583: 441–446.
O'Neill, L. A., Kishton, R. J. and Rathmell, J., A guide to immunometabolism for immunologists. Nat. Rev. Immunol. 2016. 16: 553–565.
Castro‐Dopico, T., Fleming, A., Dennison, T. W., Ferdinand, J. R., Harcourt, K., Stewart, B. J., Cader, Z., et al., GM‐CSF calibrates macrophage defense and wound healing programs during intestinal infection and inflammation. Cell Rep. 2020. 32: 107857.
Medzhitov, R. and Horng, T., Transcriptional control of the inflammatory response. Nat. Rev. Immunol. 2009. 9: 692–703.
Everts, B., Amiel, E., Van Der Windt, G. J., Freitas, T. C., Chott, R., Yarasheski, K. E., Pearce, E L., et al., Commitment to glycolysis sustains survival of NO‐producing inflammatory dendritic cells. Blood. 2012. 120: 1422–1431.
Kim, Y. E., Lee, M., Gu, H., Kim, J., Jeong, S., Yeo, S., Lee, Y. J., et al., HIF‐1α activation in myeloid cells accelerates dextran sodium sulfate‐induced colitis progression in mice. Dis. Model Mech. 2018. 11.
Macias‐Ceja, D. C., Ortiz‐Masiá, D., Salvador, P., Gisbert‐Ferrándiz, L., Hernández, C., Hausmann, M., Rogler, G., et al., Succinate receptor mediates intestinal inflammation and fibrosis. Mucosal Immunol. 2019. 12: 178–187.
Tannahill, G. M., Curtis, A. M., Adamik, J., Palsson‐McDermott, E. M., McGettrick, A. F., Goel, G., Frezza, C., et al., Succinate is an inflammatory signal that induces IL‐1β through HIF‐1α. Nature. 2013. 496: 238–242.
Clementi, E., Brown, G. C., Feelisch, M. and Moncada, S., Persistent inhibition of cell respiration by nitric oxide: crucial role of S‐nitrosylation of mitochondrial complex I and protective action of glutathione. Proc. Natl. Acad. Sci. U. S. A. 1998. 95: 7631–7636.
Lampropoulou, V., Sergushichev, A., Bambouskova, M., Nair, S., Vincent, E. E., Loginicheva, E., Cervantes‐Barragan, L., et al., itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation. Cell Metab. 2016. 24: 158–166.
Fantin, V. R., St‐Pierre, J. and Leder, P., Attenuation of LDH‐A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006. 9: 425–434.
Wang, Y., Zhao, X., Gao, Y., Zhao, C., Li, J., Wang, S., Xue, B., et al., 4‐Octyl itaconate alleviates dextran sulfate sodium‐induced ulcerative colitis in mice via activating the KEAP1‐NRF2 pathway. Inflammopharmacology. 2024.
Liao, S. T., Han, C., Xu, D. Q., Fu, X. W., Wang, J. S. and Kong, L. Y., 4‐Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to exert anti‐inflammatory effects. Nat. Commun. 2019. 10: 5091.
Zhang, D., Tang, Z., Huang, H., Zhou, G., Cui, C., Weng, Y., Liu, W., et al., Metabolic regulation of gene expression by histone lactylation. Nature. 2019. 574: 575–580.
Irizarry‐Caro, R. A., McDaniel, M. M., Overcast, G. R., Jain, V. G., Troutman, T. D. and Pasare, C., TLR signaling adapter BCAP regulates inflammatory to reparatory macrophage transition by promoting histone lactylation. Proc. Natl. Acad. Sci. U. S. A. 2020. 117: 30628–30638.
Shi, W., Cassmann, T. J., Bhagwate, A. V., Hitosugi, T. and Ip, W. K. E., Lactic acid induces transcriptional repression of macrophage inflammatory response via histone acetylation. Cell Rep. 2024. 43: 113746.
Desgeorges, T., Galle, E., Zhang, J., von Meyenn, F. and De Bock, K., Histone lactylation in macrophages is predictive for gene expression changes during ischemia induced‐muscle regeneration. Mol Metab. 2024. 83: 101923.
Tarazona, O. A. and Pourquié, O., Exploring the influence of cell metabolism on cell fate through protein post‐translational modifications. Dev. Cell. 2020. 54: 282–292.
Chen, C., Wang, Z. and Qin, Y., Connections between metabolism and epigenetics: mechanisms and novel anti‐cancer strategy. Front. Pharmacol. 2022. 13: 935536.
Ip, W. K. E., Hoshi, N., Shouval, D. S., Snapper, S. and Medzhitov, R., Anti‐inflammatory effect of IL‐10 mediated by metabolic reprogramming of macrophages. Science. 2017. 356: 513–519.
Gemperle, C., Tran, S., Schmid, M., Rimann, N., Marti‐Jaun, J., Hartling, I., Wawrzyniak, P., et al., Resolvin D1 reduces inflammation in co‐cultures of primary human macrophages and adipocytes by triggering macrophages. Prostaglandins Leukot. Essent. Fatty Acids. 2021. 174: 102363.
Shan, K., Feng, N., Cui, J., Wang, S., Qu, H., Fu, G., Li, J., et al., Resolvin D1 and D2 inhibit tumour growth and inflammation via modulating macrophage polarization. J. Cell. Mol. Med. 2020. 24: 8045–8056.
Yuan, J., Lin, F., Chen, L., Chen, W., Pan, X., Bai, Y., Cai, Y., et al., Lipoxin A4 regulates M1/M2 macrophage polarization via FPR2‐IRF pathway. Inflammopharmacology. 2022. 30: 487–498.
Van den Bossche, J., Baardman, J., Otto, N. A., Van Der Velden, S., Neele, A. E., Van Den Berg, S. M., Luque‐Martin, R., et al., Mitochondrial dysfunction prevents repolarization of inflammatory macrophages. Cell Rep. 2016. 17: 684–696.
Wculek, S. K., Heras‐Murillo, I., Mastrangelo, A., Mañanes, D., Galán, M., Miguel, V., Curtabbi, A., et al., Oxidative phosphorylation selectively orchestrates tissue macrophage homeostasis. Immunity. 2023. 56: 516–530.e9.
Minton, K., Immune regulation: IL‐10 targets macrophage metabolism. Nat. Rev. Immunol. 2017. 17: 345.
Wilson, J. L., Nägele, T., Linke, M., Demel, F., Fritsch, S. D., Mayr, H. K., Cai, Z., et al., Inverse data‐driven modeling and multiomics analysis reveals Phgdh as a metabolic checkpoint of macrophage polarization and proliferation. Cell Rep. 2020. 30: 1542–1552.e7.
Cai, Z., Li, W., Hager, S., Wilson, J. L., Afjehi‐Sadat, L., Heiss, E. H., Weichhart, T., et al., Targeting PHGDH reverses the immunosuppressive phenotype of tumor‐associated macrophages through α‐ketoglutarate and mTORC1 signaling. Cell Mol Immunol. 2024. 21: 448–465.
Min, B. K., Park, S., Kang, H. J., Kim, D. W., Ham, H. J., Ha, C. M., Choi, B. J., et al., Pyruvate dehydrogenase kinase is a metabolic checkpoint for polarization of macrophages to the M1 phenotype. Front. Immunol. 2019. 10: 944.
D'Avola, A., Legrave, N., Tajan, M., Chakravarty, P., Shearer, R. L., King, H. W., Kluckova, K., et al., PHGDH is required for germinal center formation and is a therapeutic target in MYC‐driven lymphoma. J. Clin. Invest. 2022. 132.
Samanta, D., Park, Y., Andrabi, S. A., Shelton, L. M., Gilkes, D. M. and Semenza, G. L., PHGDH expression is required for mitochondrial redox homeostasis, breast cancer stem cell maintenance, and lung metastasis. Cancer Res. 2016. 76: 4430–4442.
Zhang, X. and Bai, W., Repression of phosphoglycerate dehydrogenase sensitizes triple‐negative breast cancer to doxorubicin. Cancer Chemother. Pharmacol. 2016. 78: 655–659.
Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E., Kim, D., Birsoy, K., Sethumadhavan, S., et al., Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011. 476: 346–350.
Li, M., Wu, C., Yang, Y., Zheng, M., Yu, S., Wang, J., Chen, L., et al., 3‐Phosphoglycerate dehydrogenase: a potential target for cancer treatment. Cell Oncol (Dordr). 2021. 44: 541–556.
Carrillo, A. E. and Vliora, M., Adipose tissue metabolism in response to food intake. Nutrients. 2023. 15.
Xia, Y., Li, Y., Wu, X., Zhang, Q., Chen, S., Ma, X. and Yu, M., Ironing out the details: how iron orchestrates macrophage polarization. Front. Immunol. 2021. 12: 669566.
Sukhbaatar, N. and Weichhart, T., Iron regulation: macrophages in control. Pharmaceuticals (Basel). 2018. 11.
Erkelens, M. N., Goverse, G., Konijn, T., Molenaar, R., Beijer, M. R., Van Den Bossche, J., De Goede, K E., et al., Intestinal macrophages balance inflammatory expression profiles via vitamin A and dectin‐1‐mediated signaling. Front. Immunol. 2020. 11.
Ang, A., Pullar, J. M. and Currie, M. J., Vissers MCM. Vitamin C and immune cell function in inflammation and cancer. Biochem. Soc. Trans. 2018. 46: 1147–1159.
Mohammed, B. M., Fisher, B. J., Huynh, Q. K., Wijesinghe, D. S., Chalfant, C. E., Brophy, D. F., Fowler Iii, A A., et al., Resolution of sterile inflammation: role for vitamin C. Mediators Inflamm. 2014. 2014: 173403.
Munn, D. H. and Mellor, A. L., Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013. 34: 137–143.
Michaudel, C., Danne, C., Agus, A., Magniez, A., Aucouturier, A., Spatz, M., Lefevre, A., et al., Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases. Gut. 2023. 72: 1296–1307.
Wirthgen, E., Hoeflich, A., Rebl, A. and Günther, J., Kynurenic acid: the Janus‐faced role of an immunomodulatory tryptophan metabolite and its link to pathological conditions. Front. Immunol. 2017. 8: 1957.
Sofia, M. A., Ciorba, M. A., Meckel, K., Lim, C. K., Guillemin, G. J., Weber, C. R., Bissonnette, M., et al., Tryptophan metabolism through the kynurenine pathway is associated with endoscopic inflammation in ulcerative colitis. Inflamm. Bowel Dis. 2018. 24: 1471–1480.
Ni, S., Yuan, Y., Kuang, Y. and Li, X., Iron metabolism and immune regulation. Front. Immunol. 2022. 13: 816282.
Völlger, L., Akong‐Moore, K., Cox, L., Goldmann, O., Wang, Y., Schäfer, S. T., Naim, H. Y., et al., Iron‐chelating agent desferrioxamine stimulates formation of neutrophil extracellular traps (NETs) in human blood‐derived neutrophils. Biosci. Rep. 2016. 36.
Pereira, M., Chen, T. D., Buang, N., Olona, A., Ko, J. H., Prendecki, M., Costa, A. S. H., et al., Acute iron deprivation reprograms human macrophage metabolism and reduces inflammation in vivo. Cell Rep. 2019. 28: 498–511.e5.
Castoldi, A., Naffah de Souza, C., Câmara, N. O. and Moraes‐Vieira P. M., The macrophage switch in obesity development. Front. Immunol. 2015. 6: 637.
Varaeva, Y. R., Kirichenko, T. V., Shaposhnikova, N. N., Nikityuk, D. B. and Starodubova, A. V., The role of diet in regulation of macrophages functioning. Biomedicines. 2022. 10.
Park, H., Yu, S. and Kim, W., Rice bran oil attenuates chronic inflammation by inducing M2 macrophage switching in high‐fat diet‐fed obese mice. Foods. 2021. 10.
Shao, D., Lian, Z., Di, Y., Zhang, L., Rajoka, M. S. R., Zhang, Y., Kong, J., et al., Dietary compounds have potential in controlling atherosclerosis by modulating macrophage cholesterol metabolism and inflammation via miRNA. NPJ Sci Food. 2018. 2: 13.
D'Esposito, V., Di Tolla, M. F., Lecce, M., Cavalli, F., Libutti, M., Misso, S., Cabaro, S., et al., Lifestyle and dietary habits affect plasma levels of specific cytokines in healthy subjects. Front. Nutr. 2022. 9: 913176.
Rohm, T. V., Keller, L., Bosch, A. J. T., AlAsfoor, S., Baumann, Z., Thomas, A., Wiedemann, S J., et al., Targeting colonic macrophages improves glycemic control in high‐fat diet‐induced obesity. Commun. Biol. 2022. 5: 370.
Rohm, T. V., Fuchs, R., Müller, R. L., Keller, L., Baumann, Z., Bosch, A. J. T., Schneider, R., et al., Obesity in humans is characterized by gut inflammation as shown by pro‐inflammatory intestinal macrophage accumulation. Front. Immunol. 2021. 12.
Miranda, P. M., De Palma, G., Serkis, V., Lu, J., Louis‐Auguste, M. P., McCarville, J. L., Verdu, E F., et al., High salt diet exacerbates colitis in mice by decreasing Lactobacillus levels and butyrate production. Microbiome. 2018. 6: 57.
Tan, J. K., Macia, L. and Mackay, C. R., Dietary fiber and SCFAs in the regulation of mucosal immunity. J. Allergy Clin. Immunol. 2023. 151: 361–370.
Scott, N. A., Andrusaite, A., Andersen, P., Lawson, M., Alcon‐Giner, C., Leclaire, C., Verdu, E F., et al., Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis. Sci. Transl. Med. 2018. 10.
Chen, Q., Nair, S. and Ruedl, C., Microbiota regulates the turnover kinetics of gut macrophages in health and inflammation. Life Sci. Alliance. 2022. 5.
Shaw, T. N., Houston, S. A., Wemyss, K., Bridgeman, H. M., Barbera, T. A., Zangerle‐Murray, T., Strangward, P., et al., Tissue‐resident macrophages in the intestine are long lived and defined by Tim‐4 and CD4 expression. J. Exp. Med. 2018. 215: 1507–1518.
Bain, C. C., Bravo‐Blas, A., Scott, C. L., Perdiguero, E. G., Geissmann, F., Henri, S., Malissen, B., et al., Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat. Immunol. 2014. 15: 929–937.
Kang, B., Alvarado, L. J., Kim, T., Lehmann, M. L., Cho, H., He, J., Li, P., et al., Commensal microbiota drive the functional diversification of colon macrophages. Mucosal. Immunol. 2020. 13: 216–229.
Honda, M., Surewaard, B. G. J., Watanabe, M., Hedrick, C. C., Lee, W. Y., Brown, K., Mccoy, K D., et al., Perivascular localization of macrophages in the intestinal mucosa is regulated by Nr4a1 and the microbiome. Nat. Commun. 2020. 11: 1329.
Alrafas, H. R., Busbee, P. B., Nagarkatti, M. and Nagarkatti, P. S., Resveratrol modulates the gut microbiota to prevent murine colitis development through induction of Tregs and suppression of Th17 cells. J. Leukoc. Biol. 2019. 106: 467–480.
O'Connor, K., Morrissette, M., Strandwitz, P., Ghiglieri, M., Caboni, M., Liu, H., Khoo, C., et al., Cranberry extracts promote growth of Bacteroidaceae and decrease abundance of Enterobacteriaceae in a human gut simulator model. PLoS One. 2019. 14: e0224836.
Hussain, T., Tan, B., Yin, Y., Blachier, F., Tossou, M. C. and Rahu, N., Oxidative stress and inflammation: what polyphenols can do for us? Oxid. Med. Cell Longev. 2016. 2016: 7432797.
Mao, X., Gu, C., Chen, D., Yu, B. and He, J., Oxidative stress‐induced diseases and tea polyphenols. Oncotarget. 2017. 8: 81649–81661.
Li, G‐l, Tang, J‐f, Tan, W‐l, Zhang, T., Zeng, D., Zhao, S., Ran, J. H., et al., The anti‐hepatocellular carcinoma effects of polysaccharides from Ganoderma lucidum by regulating macrophage polarization via the MAPK/NF‐κB signaling pathway. Food & Function. 2023. 14: 3155–3168.
Deng, J., Ibrahim, M. S., Tan, L. Y., Yeo, X. Y., Lee, Y. A., Park, S. J., Wüstefeld, T., et al., Microplastics released from food containers can suppress lysosomal activity in mouse macrophages. J. Hazard. Mater. 2022. 435: 128980.
Pagano, E., Romano, B., Izzo, A. A. and Borrelli, F., The clinical efficacy of curcumin‐containing nutraceuticals: an overview of systematic reviews. Pharmacol. Res. 2018. 134: 79–91.
Pagano, E. and Izzo, A. A., Potential of phytochemicals in breast cancer prevention and therapy. Phytother. Res. 2019. 33: 2795–2797.
Arango Duque, G. and Descoteaux, A., Macrophage cytokines: involvement in immunity and infectious diseases. Front. Immunol. 2014. 5: 491.
Jang, D. I., Lee, A. H., Shin, H. Y., Song, H. R., Park, J. H., Kang, T. B., Lee, S. R., et al., The role of tumor necrosis factor alpha (TNF‐α) in autoimmune disease and current TNF‐α inhibitors in therapeutics. Int. J. Mol. Sci. 2021. 22.
Tursi, A., Mocci, G., Lorenzetti, R., Allegretta, L., Brandimarte, G., Cassieri, C., Colucci, R., et al., Long‐term real‐life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients. Eur. J. Gastroenterol. Hepatol. 2021. 33: 670–679.
StatPearls. 2024.
Leone, G. M., Mangano, K., Petralia, M. C., Nicoletti, F. and Fagone, P., Past, present and (foreseeable) future of biological anti‐TNF alpha therapy. J. Clin. Med. 2023. 12.
Celis, R., Cuervo, A., Ramírez, J. and Cañete, J. D., Psoriatic synovitis: singularity and potential clinical implications. Front Med (Lausanne). 2019. 6: 14.
Koelink, P. J., Bloemendaal, F. M., Li, B., Westera, L., Vogels, E. W. M., Van Roest, M., Gloudemans, A. K., et al., Anti‐TNF therapy in IBD exerts its therapeutic effect through macrophage IL‐10 signalling. Gut. 2020. 69: 1053–1063.
Alderson, M. R., Armitage, R. J., Tough, T. W., Strockbine, L., Fanslow, W. C. and Spriggs, M. K., CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J. Exp. Med. 1993. 178: 669–674.
Fries, K. M., Sempowski, G. D., Gaspari, A. A., Blieden, T., Looney, R. J. and Phipps, R. P., CD40 expression by human fibroblasts. Clin. Immunol. Immunopathol. 1995. 77: 42–51.
Hollenbaugh, D., Mischel‐Petty, N., Edwards, C. P., Simon, J. C., Denfeld, R. W., Kiener, P. A. and Aruffo, A., Expression of functional CD40 by vascular endothelial cells. J. Exp. Med. 1995. 182: 33–40.
Bullock, T. N. J., CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies. Cell Mol Immunol. 2022. 19: 14–22.
Karnell, J. L., Rieder, S. A., Ettinger, R. and Kolbeck, R., Targeting the CD40‐CD40L pathway in autoimmune diseases: humoral immunity and beyond. Adv. Drug. Deliv. Rev. 2019. 141: 92–103.
Pittet, M. J., Michielin, O. and Migliorini, D., Clinical relevance of tumour‐associated macrophages. Nat. Rev. Clin. Oncol. 2022. 19: 402–421.
Herrera‐deGuise, C., Serra‐Ruiz, X., Lastiri, E. and Borruel, N., JAK inhibitors: a new dawn for oral therapies in inflammatory bowel diseases. Front Med (Lausanne). 2023. 10: 1089099.
Duggan, S. and Keam, S. J., Upadacitinib: first approval. Drugs. 2019. 79: 1819–1828.
Yu, J., Shen, Y., Luo, J., Jin, J., Li, P., Feng, P. and Guan, H., Upadacitinib inhibits corneal inflammation and neovascularization by suppressing M1 macrophage infiltration in the corneal alkali burn model. Int. Immunopharmacol. 2023. 116: 109680.
López‐Navarro, B., Simón‐Fuentes, M., Ríos, I., Schiaffino, M. T., Sanchez, A., Torres‐Torresano, M., Nieto‐Valle, A., et al., Macrophage re‐programming by JAK inhibitors relies on MAFB. Cell. Mol. Life Sci. 2024. 81: 152.
Spiewak, T. A. and Patel, A., User's guide to JAK inhibitors in inflammatory bowel disease. Curr. Res. Pharmacol. Drug Discov. 2022. 3: 100096.
Liu, E., Aslam, N., Nigam, G. and Limdi, J. K., Tofacitinib and newer JAK inhibitors in inflammatory bowel disease‐where we are and where we are going. Drugs Context. 2022. 11.
Zak, J., Pratumchai, I., Marro, B. S., Marquardt, K. L., Zavareh, R. B., Lairson, L. L., Oldstone, M. B. A., et al., Myeloid reprogramming by JAK inhibition enhances checkpoint blockade therapy. Biorxiv. 2022: 2022.06.24.497435.
Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., Schmierer, M., et al., Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 2020. 38: 947–953.
Zhang, W., Liu, L., Su, H., Liu, Q., Shen, J., Dai, H., Zheng, W., et al., Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br. J. Cancer. 2019. 121: 837–845.
Kaczanowska, S., Beury, D. W., Gopalan, V., Tycko, A. K., Qin, H., Clements, M. E., Drake, J., et al., Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis. Cell. 2021. 184: 2033–2052.e21.
Zhang, L., Tian, L., Dai, X., Yu, H., Wang, J., Lei, A., Zhu, M., et al., Pluripotent stem cell‐derived CAR‐macrophage cells with antigen‐dependent anti‐cancer cell functions. J. Hematol. Oncol. 2020. 13: 153.
Kang, M., Lee, S. H., Kwon, M., Byun, J., Kim, D., Kim, C., Koo, S., et al., Nanocomplex‐mediated in vivo programming to chimeric antigen receptor‐m1 macrophages for cancer therapy. Adv. Mater. 2021. 33: e2103258.
KAaYYaUNTaJMLaGSaDECaCJaAMaSOa, R., A phase 1, first‐in‐human (FIH) study of the anti‐HER2 CAR macrophage CT‐0508 in subjects with HER2 overexpressing solid tumors. Journal of Clinical Oncology. 2022. 40: 2533–.
Carisma Therapeutics Inc. CAR‐macrophages for the Treatment of HER2 Overexpressing Solid Tumors. 2024. Report No.: NCT04660929.
Washington University School of Medicine. FOLFIRINOX Plus PF‐04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. 2016. Report No.: NCT01413022.
Perdiguero, E. G. and Geissmann, F., The development and maintenance of resident macrophages. Nat. Immunol. 2016. 17: 2–8.
Stanley, E. R. and Chitu, V., CSF‐1 receptor signaling in myeloid cells. Cold Spring Harb. Perspect. Biol. 2014. 6.
Lin, W., Xu, D., Austin, C. D., Caplazi, P., Senger, K., Sun, Y., Jeet, S., et al., Function of CSF1 and IL34 in macrophage homeostasis, inflammation, and cancer. Front Immunol. 2019. 10: 2019.
Pognan, F., Buono, C., Couttet, P., Galarneau, J. R., Timsit, Y. and Wolf, A., Liver enzyme delayed clearance in rat treated by CSF1 receptor specific antagonist Sotuletinib. Curr Res Toxicol. 2022. 3: 100091.
Lin, F., Jacqueline Kwong, W., Pan, I., Ye, X., Dai, D. and Tap W., Real‐world patient experience of pexidartinib for tenosynovial giant‐cell tumor. Oncologist. 2024. 29: e535–e43.
Healey, J. H., Tap, W. D., Gelhorn, H. L., Ye, X., Speck, R. M., Palmerini, E., Stacchiotti, S., et al., Pexidartinib provides modest pain relief in patients with tenosynovial giant cell tumor: results from ENLIVEN. Clin. Orthop. Relat. Res. 2023. 481: 107–116.
Tsou, C. L., Peters, W., Si, Y., Slaymaker, S., Aslanian, A. M., Weisberg, S. P., Mack, M., et al., Critical roles for CCR2 and MCP‐3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J. Clin. Invest. 2007. 117: 902–909.
Charo, I. F., CCR2: from cloning to the creation of knockout mice. Chem. Immunol. 1999. 72: 30–41.
Pant, A., Hwa‐Lin Bergsneider, B., Srivastava, S., Kim, T., Jain, A., Bom, S., Shah, P., et al., CCR2 and CCR5 co‐inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti‐PD‐1 therapy. Oncoimmunology. 2024. 13: 2338965.
Wang, J., Saung, M. T., Li, K., Fu, J., Fujiwara, K., Niu, N., Muth, S., et al., CCR2/CCR5 inhibitor permits the radiation‐induced effector T cell infiltration in pancreatic adenocarcinoma. J. Exp. Med. 2022. 219.
Files, D. C., Tacke, F., O'Sullivan, A., Dorr, P., Ferguson, W. G. and Powderly, W. G., Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID‐19. PLoS Pathog. 2022. 18: e1010547.
Puengel, T., Lefere, S., Hundertmark, J., Kohlhepp, M., Penners, C., Van De Velde, F., Lapauw, B., et al., Combined therapy with a CCR2/CCR5 antagonist and FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis. Int. J. Mol. Sci. 2022. 23.
de Zeeuw, D., Bekker, P., Henkel, E., Hasslacher, C., Gouni‐Berthold, I., Mehling, H., Potarca, A., et al., The effect of CCR2 inhibitor CCX140‐B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet. Diabetes Endocrinol. 2015. 3: 687–696.
Haringman, J. J., Gerlag, D. M., Smeets, T. J., Baeten, D., Van Den Bosch, F., Bresnihan, B., Breedveld, F C., et al., A randomized controlled trial with an anti‐CCL2 (anti‐monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 2006. 54: 2387–2392.
Vergunst, C. E., Gerlag, D. M., Lopatinskaya, L., Klareskog, L., Smith, M. D., Van Den Bosch, F., Dinant, H J., et al., Modulation of CCR2 in rheumatoid arthritis: a double‐blind, randomized, placebo‐controlled clinical trial. Arthritis Rheum. 2008. 58: 1931–1939.
Ratziu, V., Sanyal, A., Harrison, S. A., Wong, V. W., Francque, S., Goodman, Z., Aithal, G P., et al., Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the Phase 2b CENTAUR study. Hepatology. 2020. 72: 892–905.
Gulick, R. M., Fatkenheuer, G., Burnside, R., Hardy, W. D., Nelson, M. R., Goodrich, J., Mukwaya, G., et al., Five‐year safety evaluation of maraviroc in HIV‐1‐infected treatment‐experienced patients. J. Acquir. Immune Defic. Syndr. 2014. 65: 78–81.
Dawson, J. R. D., Wadman, G. M., Zhang, P., Tebben, A., Carter, P. H., Gu, S., Shroka, T., et al., Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5. Biorxiv. 2024: 2023.11.15.567150.
Gorfu, G., Rivera‐Nieves, J. and Ley, K., Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr. Mol. Med. 2009. 9: 836–850.
Schleier, L., Wiendl, M., Heidbreder, K., Binder, M. T., Atreya, R., Rath, T., Becker, E., et al., Non‐classical monocyte homing to the gut via α4β7 integrin mediates macrophage‐dependent intestinal wound healing. Gut. 2020. 69: 252–263.
Sommer, K., Heidbreder, K., Kreiss, L., Dedden, M., Paap, E. M., Wiendl, M., et al., Anti‐β7 integrin treatment impedes the recruitment on non‐classical monocytes to the gut and delays macrophage‐mediated intestinal wound healing. Clin. Transl. Med. 2023. 13: e1233.
Wang, Y. N., Wang, Y. Y., Wang, J., Bai, W. J. and Miao, N. J., Vinblastine resets tumor‐associated macrophages toward M1 phenotype and promotes antitumor immune response. J. Immunother. Cancer. 2023. 11: e007253.